UnitedHealthcare respiratory nucleic acid coverage update

Coverage and Medical Necessity Criteria

inv-01: Not Medically Necessary — Large Multiplex Panels in Outpatient Setting

Not medically necessary when the following condition is met:

Outpatient large-panel restriction: Respiratory pathogen panel testing of six or more targets performed in an outpatient setting>= 6 targets

Considered unproven and not medically necessary due to insufficient evidence of efficacy for all indications.

inv-02: COV ERAGE CRITERIA — Covered when ALL of the following are met for recommended patient groups (per guideline suggestions)

Covered when ALL of the following are met for recommended patient groups (per guideline suggestions):

Recommended patient groups

Examples: hematology/oncology patients OR transplant patients OR ICU patients OR pediatric patients with underlying illness OR outpatients with severe symptoms or high risk for complications

Molecular respiratory assays—including multiplex RT-PCR and metagenomic next-generation sequencing (mNGS)—detect microbial nucleic acid in respiratory specimens. Detection of a microbe by molecular methods does not confirm a viable virus or ongoing replication; results must be interpreted in the clinical context, considering possible prolonged shedding, colonization, or contamination when determining clinical significance.

The American Thoracic Society guideline for nucleic acid–based testing in adults with suspected community-acquired pneumonia issues a conditional recommendation against routine outpatient nucleic acid testing for viral pathogens other than influenza (very low–quality evidence). This suggests clinicians should not routinely order broad molecular viral panels for otherwise stable adult outpatients when influenza testing would address the clinical question.

Respiratory pathogen panel testing that interrogates six or more targets in an outpatient setting is considered unproven and not medically necessary because current evidence does not demonstrate sufficient clinical benefit across outpatient indications. Limiting large multiplex panels in outpatient care aligns with the policy position that such broad testing lacks demonstrated efficacy to change management for most ambulatory patients.

Guidelines and evidence raise questions about the value of broad multiplex respiratory testing for relatively healthy adult outpatients. The ASM guidance identifies specific high-risk groups where multiplex panels may be useful (e.g., hematology/oncology, transplant, ICU, and pediatric patients with underlying illness), while ATS guidance suggests against routine outpatient testing for noninfluenza viruses. Combined with this policy’s determination that panels with >= 6 targets are unproven in outpatient settings, clinicians should consider targeted testing (for example, influenza testing) or reserve multiplex panels for patients meeting high-risk or inpatient criteria.

Indications and Special Populations Where Multiplex Testing May Be Appropriate

inv-23: Use of mNGS and multiplex testing when conventional testing fails or rapid ID needed, particularly in complex or immunocompromised cases (evidence limited)

Covered when ALL of the following are met:

Use of advanced or multiplex testing after conventional testing: Conventional diagnostic testing has failed to identify a pathogen or rapid pathogen identification is required to guide clinical management.

mNGS has demonstrated diagnostic value for pulmonary infections and may be particularly useful when conventional tests are negative; evidence is limited and heterogeneous.

Clinical context: Testing is being considered in complex, severely ill, or immunocompromised patients where rapid or broader identification may change management

Supported by systematic review and trial data indicating potential value in these populations.

inv-24: Hospitalized patients (including ICU), immunocompromised, hematology/oncology/transplant, and pediatric patients with underlying illness as appropriate candidates

Procedure Codes and Panel Size Threshold

Proprietary U-codes (larger panels)mixed

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.

Mixed U-codes and CPT codes (various panel sizes)mixed

0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

inv-09: Panel target count threshold — >= 6 targets

Panel target count threshold>= 6 targets

Policy rationalePanels of six or more targets are considered unproven and not medically necessary in outpatient settings due to insufficient evidence of efficacy.

Associated CPT/U-codesExamples include CPT 87632 (6-11 targets) and 87633 (12-25 targets), and U-codes such as 0556U, 0563U, 0564U for multi-target proprietary panels.

Authorization, Documentation, and Ordering Guidance for Providers

Prior Authorization

Tests and codes potentially requiring authorization

The policy identifies procedure codes for respiratory pathogen nucleic acid detection tests (CPT 87632, 87633 and U‑codes 0115U, 0202U, 0223U, 0225U, 0556U, 0563U, 0564U). Panels that meet the policy's not‑medically‑necessary criteria (panels of six or more targets in outpatients) are subject to denial; obtain and retain medical‑necessity documentation or follow plan prior‑authorization rules when ordering these tests.

Referenced codes: 0115U, 0202U, 0223U, 0225U, 0556U, 0563U, 0564U, 87632, 87633
Panels >= 6 targets in outpatient setting are considered unproven and not medically necessary

Note

Authorization and reimbursement reference

Follow UnitedHealthcare reimbursement rules and the Laboratory Services Policy; check federal, state, and contractual benefit terms before relying on this policy for coverage or billing decisions.

Added reference to Laboratory Services Policy, Professional (Policy History)

Ordering and Documentation Expectations

Documentation Required

Ordering documentation — medical necessity must be documented

Although the policy does not define explicit medical‑necessity documentation fields, ordering providers should document the clinical rationale and medical necessity when ordering multiplex molecular tests.

Policy provides code lists and clinical rationale but does not specify exact documentation templates
Detection of nucleic acid does not confirm viable pathogen—interpretation must be documented in clinical context

Billing Rule

Ordering requirements — follow contractual and plan rules

Ensure orders comply with UnitedHealthcare contractual, federal, and state benefit plan requirements and any applicable Laboratory Services Policy guidance before requesting coverage.

Services Not Covered Under This Policy

NOT COVERED: Respiratory pathogen panel testing of six or more targets performed in an outpatient setting is not covered. Tests meeting this threshold are considered unproven and not medically necessary for outpatient care and may be denied unless the clinical scenario clearly meets covered high-risk criteria.

NOT COVERED: Routine multiplex testing of relatively healthy adult outpatients for viral pathogens other than influenza, and additional broad multiplex testing in outpatient settings where targeted influenza testing would suffice, are considered not covered or not routinely necessary based on guideline recommendations and the limited evidence of outpatient benefit.

Frequency and Repeat Testing

inv-25: Not specified in this portion of the document

Frequency limits specifiedNot specified in this portion of the document.

Guidance for coverage decisionsRefer to federal, state, or contractual benefit plan requirements and UnitedHealthcare reimbursement rules when determining applicability of any frequency restrictions.

Implication for orderingOrdering providers should document medical necessity and clinical context; no explicit repeat-test intervals are provided here.

inv-26: No explicit frequency limits stated in this document

Explicit frequency limitsNo explicit frequency limits stated in this document.

Operational noteCoverage determinations should reference applicable benefit plan terms; policy does not define test repetition intervals.

Background and Technology Overview

Background: Multiplex molecular respiratory assays (including multiplex RT-PCR and mNGS) detect nucleic acids from multiple respiratory pathogens in a single specimen, allowing rapid identification compared with culture. These assays identify predefined viral and bacterial genetic targets or, in the case of mNGS, broadly survey all nucleic acids in a sample. Limitations include that nucleic acid detection does not prove viable organisms or active replication, variable clinical-actionability across pathogens, and limited outcome-based evidence supporting routine use of large panels (>= 6 targets) in outpatient populations. Clinical guidelines emphasize use in specific higher-risk populations rather than routine outpatient screening.

Definitions

inv-19: mNGS — Metagenomic next-generation sequencing (definition)

DefinitionMetagenomic next-generation sequencing (mNGS) enables comprehensive detection of all genes from all organisms within a sample by comparing nucleic acid sequences extracted from a single tissue or liquid specimen.

PurposeIntended to identify pathogenic microbes responsible for bacterial, fungal, parasitic, and viral illnesses when conventional methods may fail.

Interpretation caveatDetection by mNGS does not confirm a viable organism or ongoing replication; clinical correlation is required.

inv-20: Multiplex RT-PCR — definition of multiplex reverse transcription PCR assays

DefinitionMultiplex reverse transcription - polymerase chain reaction (RT-PCR) assays identify predefined microbial RNA or nucleic acid targets in respiratory specimens, if present.

OpenPayer

Respiratory Pathogen Nucleic Acid Detection Testing (for Kansas Only)